BTAI Dividend: BioXcel Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

BTAI Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	2	1	0	0	0
Revenue Growth (YoY)	-100%	100%	--	--	--	--
Cost of Revenue	0	2	1	0	--	--
Gross Profit	0	0	0	0	--	--
Selling, General & Admin	20	34	83	68	54	24
Research & Development	29	30	84	91	52	58
Operating Expenses	50	64	167	160	106	82
Other Non Operating Income (Expenses)	-2	20	0	0	--	--
Pretax Income	-68	-59	-179	-165	-106	-82
Income Tax Expense	--	--	--	--	--	--
Net Income	-68	-59	-179	-165	-106	-82
Net Income Growth	-3%	-67%	8%	56%	28.99%	156%
Shares Outstanding (Diluted)	14.19	2.53	1.82	1.75	1.64	1.35
Shares Change (YoY)	436%	39%	4%	6%	22%	33%
EPS (Diluted)	-4.8	-23.51	-98.35	-94.66	-64.87	-60.63
EPS Growth	-82%	-76%	4%	46%	7%	87%
Free Cash Flow	-58	-72	-155	-135	-82	-66
Free Cash Flow Per Share	-4.08	-28.4	-85.13	-77.1	-49.74	-48.7
Gross Margin	0%	0%	0%	0%	--	--
Operating Margin	0%	-3,200%	-16,700%	0%	0%	0%
Profit Margin	0%	-2,950%	-17,900%	0%	0%	0%
Free Cash Flow Margin	0%	-3,600%	-15,500%	0%	0%	0%
EBITDA	-50	-64	-167	-159	-106	-82
EBITDA Margin	0%	-3,200%	-16,700%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-50	-64	-167	-159	-106	-82
EBIT Margin	0%	-3,200%	-16,700%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	--